Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective observational study of fosnetupitant for long-delayed chemotherapy-induced nausea and vomiting with platinum-based chemotherapy (LODEC-N)
jRCT1030230130Recruiting
- Sponsor
- Tomoki
- Start
- Jun 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of fosnetupitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Tomoki. Primary endpoint: Long-delayed complete control rate (first cycle). Started Jun 2023; status: recruiting.
02
Drugs
fosnetupitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on jRCT1030230130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030230130.